Long-term HIV dynamic models incorporating drug adherence and resistance to treatment for prediction of virological responses

Computational Statistics and Data Analysis

Volumn 52, Issue 7, 2008, Pages 3765-3778

  Huang, Yangxin ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESION; DIFFERENTIAL EQUATIONS; DRUG PRODUCTS; DYNAMIC MODELS; PARAMETERIZATION; VIRUSES;

ADHERENCE; DRUG ADHERENCE; VIROLOGICAL FAILURE;

PATIENT TREATMENT;

EID: 40449119394     PISSN: 01679473     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.csda.2007.12.016     Document Type: Article

References (49)

1. Acosta E.P., Wu H., Walawander A., Eron J., Pettinelli C., Yu S., Neath D., Ferguson E., Saah A.J., Kuritzkes D.R., Gerber J.G., and for the Adult ACTG 5055 Protocol Team. Comparison of two indinavir/ritonavir regimens in treatment-experienced HIV-infected individuals. Journal of Acquired Immune Deficiency Syndromes 37 (2004) 1358-1366
2. Akaike H. Information theory and an extension of the maximum likelihood principle. In: Petrov B.N., and Csáki F. (Eds). 2nd International Symposium on Information Theory (1973), Akadémiai Kiadó, Budapest 267-281
3. Bangsberg D.R., Hecht F.M., Charlebois E.D., Zolopa A.R., Holodniy M., Sheiner L., Bamberger J.D., Chesney M.A., and Moss A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14 (2000) 357-366
4. Berg A., Meyer R., and Yu J. Deviance information criterion for comparing stochastic volatility models. Journal of Business & Economic Statistics 22 (2004) 107-120
5. Bonhoeffer S., Lipsitch M., and Levin B.R. Evaluating treatment protocols to prevent antibiotic resistance. Proc. Natl. Acad. Sci. USA 94 (1997) 12106-12111
6. Callaway D.S., and Perelson A.S. HIV-1 infection and low steady state viral loads. Bulletin of Mathematical Biology 64 (2002) 29-64
7. Cobelli C., Lepschy A., and Jacur G.R. Identifiability of compartmental systems and related structural properties. Mathematical Biosciences 44 (1979) 1-18
8. Davidian M., and Giltinan D.M. Nonlinear Models for Repeated Measurement Data (1995), Chapman & Hall, London
9. Ding A.A., and Wu H. A comparison study of models and fitting procedures for biphasic viral decay rates in viral dynamic models. Biometrics 56 (2000) 16-23
10. Gamerman D. Markov Chain Monte Carlo: Stochastic Simulation for Bayesian Inference (1997), Chapman & Hall, Londan
11. Geman S., and Geman D. Stochastic relaxation, Gibbs distributions, and the Bayesian restoration of images. IEEE Transactions on Pattern Recognition and Machine Intelligence 6 (1984) 721-741
12. Gelfand A.E., and Smith A.F.M. Sampling-based approaches to calculating marginal densities. Journal of the American Statistical Association 85 (1990) 398-409
13. In: Gilks W.R., Richardson S., and Spiegelhalter D.J. (Eds). Markov Chain Monte Carlo in Practice (1995), Chapman & Hall, Londan
14. Haas D.W., et al. Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: A randomized, double-blind, placebo-controled trial. Journal of Infectious Diseases 183 3 (2001) 392-400
15. Hammer S.M., Vaida F., et al. Dual vs. single protease inhibitor therapy following antiretroviral treatment failure: A random trial. Journal of the American Medical Association 288 (2002) 169-180
16. Han C., Chaloner K., and Perelson A.S. Bayesian analysis of a population HIV dynamic model. In: Gatsoiquiry C., Kass R.E., Carriquiry A., Gelman A., Higdon D., Pauler D.K., and Verdinellinis I. (Eds). Case Studies in Bayesian Statistics vol. 6 (2002), Springer-Verlag, New York 223-237
17. Ho D.D., Neumann A.U., Perelson A.S., Chen W., Leonard J.M., and Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373 (1995) 123-126
18. Huang Y., Rosenkranz S.L., and Wu H. Modeling HIV dynamics and antiviral responses with consideration of time-varying drug exposures, sensitivities and adherence. Mathematical Biosciences 184 (2003) 165-186
19. Huang Y., and Wu H. A Bayesian approach for estimating antiviral efficacy in HIV dynamic model. Journal of Applied Statistics 33 (2005) 155-174
20. Huang Y., Liu D., and Wu H. Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system. Biometrics 62 (2006) 413-423
21. Ickovics J.R., and Meisler A.W. Adherence in AIDS clinical trial: A framework for clinical research and clinical care. Journal of Clinical Epidemiology 50 (1997) 385-391
22. IMSL MATH/LIBRARY. FORTRAN Subroutines for Mathematical Applications vol. 2 (1994), Visual Numerics, Inc., Houston
23. Jackson R.C. A pharmacokinetic-pharmacodynamic model of chemotherapy of human immunodeficiency virus infection that relates development of drug resistance to treatment intensity. Journal of Pharmacokinetics and Pharmacodynamics 25 (1997) 713-730
24. Labbé L., and Verttoa D. A nonlinear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients. Journal of Pharmacokinetics and Pharmacodynamics 33 (2006) 519-542
25. Molla A., Korneyeva M., et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine 2 (1996) 760-766
26. Nowak M.A., Bonhoeffer S., et al. HIV results in the frame. Nature 375 (1995) 193
27. Nowak M.A., and May R.M. Virus Dynamics: Mathematical Principles of Immunology and Virology (2000), Oxford University Press, Oxford
28. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., and Ho D.D. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 271 (1996) 1582-1586
29. Perelson A.S., Essunger P., Cao Y., Vesanen M., Hurley A., Saksela K., Markowitz M., and Ho D.D. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387 (1997) 188-191
30. Perelson A.S., and Nelson P.W. Mathematical analysis of HIV-1 dynamics in vivo. SIAM Review 41 (1999) 3-44
31. Pfister M., Labbe L., Hammer S.M., Mellors J., Bennett K.K., Rosenkranz S.L., Sheiner L.B., and the AIDS Clinical Trial Group Protocol 398 Investigators. Population pharmacokinetics and pharmacodynamics of Efavirenz, Nelfinavir, and Indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrobial Agents and Chemoterapy 47 (2003) 130-137
32. Pinherio J., and Bates D.M. Mixed-effects Models in S and S-plus (2000), Springer, New York
33. SAS Institute Inc. SAS/STAT User's Guide, Version 8 (2000), SAS Publishing
34. Sheiner L.B. Modeling pharmacodynamics: Parametric and nonparametric approaches. In: Rowland M., et al. (Ed). Variability in Drug Therapy: Description, Estimation, and Control (1985), Raven Press, New York 139-152
35. Spiegelhalter D.J., Best N.G., Carlin B.P., and van der Linde A. Bayesian measures of model complexity and fit. Journal of the Royal Statistics Society, Series B 64 (2002) 583-639
36. Spiegelhalter D.J., Abrams K.R., and Myles J.P. Bayesian Approaches to Clinical Trials and Health Care Evaluation (2004), Wiley, NJ
37. Stafford M.A., et al. Modeling plasma virus concentration during primary HIV infection. Journal of Theoretical Biology 203 (2000) 285-301
38. Schwarz G. Estimating the dimension of a model. Annals of Statistics 6 (1978) 461-464
39. Verotta D. Models and estimation methods for clinical HIV-1 data. Journal of Computational and Applied Mathematics 184 (2005) 275-300
40. Vrijens B., and Goetghebeur E. Comparing compliance patterns between randomized treatments. Controlled Clinical Trials 18 (1997) 187-203
41. Vrijens B., Goetghebeur E., de Klerk E., Rode R., Mayer S., and Urquhart J. Modeling the association between adherence and viral load in HIV-infected patients. Statistics in Medicine 24 (2005) 2719-2731
42. Wahl L.M., and Nowak M.A. Adherence and resistance: Predictions for therapy outcome. Proceedings of the Royal Society, Biological 267 (2000) 835-843
43. Wainberg M.A., et al. Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase. AIDS 10 suppl (1996) S3-S10
44. Wakefield J.C., Smith A.F.M., Racine-Poon A., and Gelfand A.E. Bayesian analysis of linear and non-linear population models using the Gibbs sampler. Applied Statistics 43 (1994) 201-221
45. Wakefield J.C. The Bayesian analysis to population pharmacokinetic models. Journal of the American Statistical Association 91 (1996) 62-75
46. Wu H., Ding A.A., and de Gruttola V. Estimation of HIV dynamic parameters. Statistics in Medicine 17 (1998) 2463-2485
47. Wu H., and Ding A.A. Population HIV-1 dynamics in vivo: Applicable models and inferential tools for virological data from AIDS clinical trials. Biometrics 55 (1999) 410-418
48. Wu H., Huang Y., et al. Modeling antiretroviral response: Effects of drug potency, pharmacokinetics, adherence and drug resistance. JAIDS 39 (2005) 272-283
49. Zhu L., and Carlin B.P. Comparing hierarchical models for spatio-temporally misaligned data using the deviance information criterion. Statistics in Medicine 19 (2000) 2265-2278